← Regulatory

Clinical Trial Disruption Due to COVID-19: Interpreting and Communicating Data With Regulators

HCG hosts a panel of industry experts to discuss how to interpret data from clinical trials disrupted by the COVID-19 pandemic and how to best communicate these data with regulators. (2020).

    🕒 66 minute video

    Presenters/Moderators

    Mary Rofael, MD, RAC
    President, ProEd Regulatory
    Thomas R. Fleming, PhD
    Professor, Biostatistics and Statistics, University of Washington
    Robert Makuch, PhD
    Professor of Biostatistics and Director of the Regulatory Affairs Track, Yale University Schools of Medicine and of Public Health
    Kannan Natarajan, PhD
    Head of Global Biometrics and Data Management, Pfizer, Inc.
    Joanne Palmisano, MD, FACP, FRAPS
    Vice President, Head Global Regulatory Strategy, Vertex Pharmaceuticals, Inc.
    William White, MD
    Medical and Scientific Consultant, Professor of Medicine, Calhoun Cardiology Center, University of Connecticut School of Medicine; past president, American Society of Hypertension